Scientists Are Testing a Personalized Skin Cancer Vaccine

The vaccine essentially combines two medical technologies: the mRNA vaccine and Merck’s Keytruda. As with the COVID-19 vaccine, mRNA shots don’t require an actual virus. Instead, they use a disease’s genetic code to “teach” the immune system to recognize and fight that particular illness. This makes it relatively easy and inexpensive for scientists to develop mRNA vaccines and edit them if a new form of the disease emerges. Keytruda, meanwhile, is a prescription medication that helps prevent melanoma from coming back after known cancer cells have been surgically removed.

Moderna and Merck are testing the feasibility of not only creating a two-in-one drug with both technologies but also customizing individual vaccines to suit their respective patients. Each vaccine is engineered to activate the patient’s immune system, which in turn deploys T cells (a type of white blood cell known to fight cancer) that go after the specific mutations of a patient’s tumor. Keytruda assists this effort by barring certain cell proteins from getting in the way of T cells’ intervention.

The experimental drug is currently in its second clinical trial out of three. The trial involves 157 participants with high-risk melanoma who just successfully underwent surgical removal. Some of the participants were given the personalized vaccine, while others were given Keytruda alone. Moderna and Merck will observe whether the participants’ melanoma returns over the span of approximately one year, with primary data expected at the end of this year.

This vaccine is different from one being tested by the University of Washington Cancer Consortium, and Seattle’s Fred Hutchinson Cancer Center in collaboration with Amazon. The latter focuses on late-stage melanoma or hormone receptor-positive HER2-negative breast cancer that has either spread to other areas of the body or resisted treatment. The drug is currently being tested for safety in a trial lasting through the end of 2023.

If a vaccine preventing the recurrence of melanoma does in fact become commercially available, it could prevent more than 7,000 deaths per year in the US alone.

Continue reading

Pfizer Claims New COVID-19 Vaccine 90 Percent Effective

There have been a number of COVID-19 vaccines in development in the United States and around the world, and one of them has shown some very positive preliminary results in its Phase 3 trial. One particular vaccine developed by Pfizer and German firm BioNTech appears to be more than 90 percent effective in preventing symptomatic…

Chromebook Demand Falling as COVID Vaccination Increases

Windows demand should be buoyed by Windows 11's release, but the report predicts that Chromebook sales will continue to drop through next year.

A New Alzheimer’s Vaccine Could Be Headed for Human Trials

The treatment has shown strong effectiveness in animal models, and it could be ready for human trials in the next 18 to 24 months.